Business Context and Reporting Period
Company: Veeco Instruments Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Veeco designs, manufactures, and services process equipment and metrology tools for the data storage, high-brightness LED (HB-LED), solar, wireless, and semiconductor industries. The company operates two primary segments: Process Equipment (thin film deposition and etching) and Metrology (surface measurement tools like Atomic Force Microscopes).
Key Financial Metrics
| Metric | 2007 | 2006 | Change |
|---|---|---|---|
| Net Sales | $402.5 million | $441.0 million | (8.7%) |
| Gross Profit | $157.5 million | $194.1 million | (18.9%) |
| Gross Margin | 39.1% | 44.0% | (4.9 pts) |
| Operating Income (Loss) | $(12.1) million | $22.5 million | N/A |
| Net Income (Loss) | $(17.4) million | $14.9 million | N/A |
| Diluted EPS | $(0.56) | $0.48 | N/A |
| Cash from Operations | $39.2 million | $46.0 million | (14.8%) |
| Cash & Equivalents (End) | $117.1 million | $147.0 million | (20.3%) |
| Long-Term Debt | $121.0 million | $203.6 million | (40.6%) |
| Working Capital | $174.5 million | $248.1 million | (29.7%) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 8.7% driven by significant drops in the Data Storage (down 25.3%) and Semiconductor (down 34.8%) markets. This was partially offset by a 25.2% increase in the HB-LED/Wireless segment.
- Profitability Reversal: The company swung from a net income of $14.9 million in 2006 to a net loss of $17.4 million in 2007. Operating income turned negative due to lower sales volume, unfavorable product mix, and significant one-time charges.
- Restructuring and Impairment: The company incurred $6.7 million in restructuring expenses (severance for ~7.5% of workforce), a $4.8 million inventory write-off, and a $1.1 million asset impairment charge related to discontinued data storage product lines.
- Debt Reduction: Long-term debt decreased significantly as the company repurchased $56.0 million of convertible subordinated notes and exchanged $118.8 million of old notes for new notes maturing in 2012.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2008 Forecast: Management expects 2008 to be a recovery year, predicting revenue growth of at least 10%.
- Strategic Shift: New CEO John Peeler initiated a turnaround plan focusing on cost containment, gross margin improvement, and reallocating resources to high-growth areas (HB-LED, Solar, and Metrology).
- Future Costs: The company anticipates incurring an additional $3.5 million to $4.0 million in non-cash restructuring charges in Q1 2008 related to headquarters consolidation.
Risks and Contingencies
- Customer Concentration: Sales to Seagate Technology (10% of 2007 sales) and Hitachi (7% of 2007 sales) represent significant concentration risk.
- Supply Chain: The company relies on a sole supplier for the majority of manufacturing for new MOCVD and ion beam systems.
- Legal Proceedings:
- Patent Litigation: Ongoing lawsuit against Asylum Research Inc. regarding patent infringement; two of five patents were ruled non-infringing, but litigation continues on three others.
- Securities Litigation: Settled a securities class action for $5.5 million and a shareholder derivative suit for $0.5 million; both settlements were covered by insurance.
- Debt Maturity: $25.2 million of convertible notes mature in December 2008, requiring refinancing or conversion.
Investor Verification Checklist
- Revenue Mix: Verify the sustainability of the 25% growth in the HB-LED/Wireless segment to offset the structural decline in Data Storage.
- Restructuring Execution: Monitor the realization of cost savings from the 2007 restructuring plan and the impact of the anticipated Q1 2008 charges.
- Debt Refinancing: Assess the company's ability to refinance or convert the $25.2 million in notes maturing in late 2008.
- Supplier Dependency: Evaluate the risk associated with the sole supplier for critical MOCVD and ion beam systems.
- Legal Exposure: Track the outcome of the remaining three patents in the Asylum Research litigation and potential write-downs of capitalized legal costs.